Join VerAvanti's Early Access Program
Shape the Future of Intravascular Imaging
Be among the first to evaluate or represent VerAvanti’s pioneering SFE (Scanning Fiber Endoscope) technology. Designed to deliver real-time, forward-looking, full-color imaging, SFE sets a new standard in intravascular visualization.
Interventional Cardiologists & Vascular Surgeons
Join to evaluate VerAvanti’s SFE in complex CTO interventions and stroke procedures.
Pain Points:
Poor visualization in tortuous or occluded anatomy
Cumulative radiation exposure during complex procedures
Need for fast, real-time diagnostic feedback at the point of care
How We Plan to Help:
We will deliver high-resolution, forward-looking imaging to enhance procedural precision.
Our radiation-free, single-use design will reduce infection risk and turnaround time.
We aim to improve efficiency and confidence in treating complex lesions.
Hospitals & Academic Centers
Collaborate with us to gain early clinical experience and participate in research studies with VerAvanti’s advanced imaging technology.
Pain Points:
Delayed access to new devices limits clinical competitiveness
Limited physician access and device availability reduce procedural efficiency and revenue growth from breakthrough technologies
Pressure to publish and lead in innovation-driven specialties
How We Plan to Help:
Pursue FDA Medical Device Breakthrough Designation to enable earlier clinical access to our innovative technology
Streamline workflow and reduce overhead in high-demand intravascular procedures
Support reimbursement readiness through structured clinical use
Foster research collaborations with data access and co-authorship opportunities
Distributors & Strategic Partners
Engage with VerAvanti ahead of commercial launch to position yourself at the forefront of imaging innovation.
Pain Points:
Limited differentiation in competitive medtech markets
Demand for clinically validated, regulatory-ready products
Need for strong technical and marketing support from suppliers
How We Plan to Help:
Offer pre-market access to an imaging device with disruptive clinical potential
Empower you with robust clinical evidence, training programs, and market strategy support
Build trusted, long-term partnerships driven by global compliance and patient outcomes
Who Should Join?
VerAvanti’s Early Access program is designed for forward-thinking professionals and organizations eager to be at the forefront of intravascular innovation. Whether you're a clinician, hospital leader, or commercial partner, this is your opportunity to engage with breakthrough technology before full market release.
%20copy.jpg)
Academic Research Participation
Select institutions will contribute to structured, investigator-led studies exploring clinical applications of the SFE Partners will:
Help generate early clinical evidence
Co-author abstracts and publications
Early access to our FDA Breakthrough Device (pending clearance) to stay ahead of the competition
Early Device Access
Several SFE units will be distributed to academic centers for real-world evaluation. You will have the opportunity to:
Perform hands-on testing in clinical workflows
Share usability and performance feedback
Collect data using an exclusive pre-FDA device, helping you stay ahead and lay the foundation for long-term clinical and academic influence
Direct Access to Dr. Luis Savastano
Participate in exclusive monthly strategy sessions with our Chief Medical Officer, Dr. Luis Savastano. These virtual meeting will offer a forum for:
Real-time study updates and clinical insights
Case reviews and image analysis
Peer exchange with fellow academic collaborators
What Can You Expect?
By joining VerAvanti’s Early Access program, you will gain more than just early exposure; you will become part of a structured, research-driven initiative that helps shape the future of intravascular imaging.
Here is what participation looks like:
Register Your Interest in VerAvanti’s Early Access Program
Procedural Efficiency & Capacity
Our technology will deliver high-resolution, live imaging designed to accelerate workflows and enhance procedural throughput. This will improve accuracy and reduce time spent on each case, leading to better patient outcomes.
Fiber Optic Technology
Utilizing advanced fiber optics, our system will provide vivid, high-resolution live images with exceptional clarity and color fidelity. This precision will support detailed visualization of complex anatomy.
Minimal Invasiveness
Our technology will support minimally invasive procedures by providing real-time, high-resolution imaging that guides clinicians with precision, minimizing tissue trauma and enhancing recovery.
Radiation Free, Single-Use Design
Our device will offer radiation-free imaging through a disposable, single-use design that eliminates contamination risks and the need for sterilization, improving safety and operational efficiency.
Diagnostic Accuracy
We will deliver clear, high-resolution visuals that enable clinicians to make accurate, real-time diagnoses, reducing the need for repeat interventions and enabling targeted treatments.
Real-Time Visual Feedback
Our system will provide immediate, live imaging feedback during procedures, empowering clinicians to adjust techniques dynamically and improve procedural success rates.
Why Join Our Early Access Program?
VerAvanti will transform how clinicians visualize and treat chronic total occlusions (CTOs), strokes, and other intravascular diseases. Although our products are not yet commercially available, we are actively advancing through the U.S. FDA review process, with clearance expected in the first half of 2026. We will then pursue CE marking for the EU and UK shortly thereafter. For markets outside North America and Europe, we plan to begin pursuing local regulatory approvals in early 2027.
Our patented SFE technology will deliver:
Meet our Key Leader
Dr. Luis Savastano
Chief Medical Officer, VerAvanti | Neurosurgeon & Imaging Innovator
Dr. Luis Savastano is a surgeon-scientist, inventor, and serial founder dedicated to solving unmet clinical needs through translational research and the development of breakthrough medical technologies. A hybrid cerebrovascular neurosurgeon, he specializes in both microsurgical and endovascular treatment of ischemic and hemorrhagic stroke.
He currently serves at the University of California, San Francisco (UCSF) as Co-Chief of NeuroEndovascular Surgery, Medical Director of Cerebrovascular Neurosurgery, Program Director of the CAST-approved Cerebrovascular Fellowship, and Principal Investigator of the Translational Neurosurgery and Technology Lab (TNTLab). In these roles, Dr. Savastano leads a multidisciplinary team working at the intersection of clinical care, innovation, and device development.
As Chief Medical Officer at VerAvanti, Dr. Savastano plays a key role in shaping the company’s clinical research and validation strategy. He leads efforts to advance the SFE angioscopy platform through investigator-led studies and strategic collaborations with early access partners. Through regular research meetings and case-based discussions, he works closely with academic institutions and practicing clinicians to refine the technology and accelerate its path to clinical adoption.
Dr. Savastano has conducted pioneering research on VerAvanti’s SFE platform and was among the earliest to explore its use in the evaluation of carotid artery disease and stroke, demonstrating its potential to provide real-time, high-resolution intravascular visualization. His work underscores a strong commitment to translating innovation into meaningful clinical tools that improve outcomes and reshape standards of care.